EGFR Blockade Reverses Cisplatin Resistance in Human Epithelial Ovarian Cancer Cells.

ABSTRACT:

Background

Epithelial ovarian cancer (EOC) is one of the most lethal gynecological malignancy worldwide. Although the majority of EOC patients achieve clinical remission after induction therapy, over 80% relapse and succumb to the chemoresistant disease. Previous investigations have demonstrated the association of epidermal growth factor receptor (EGFR) with resistance to cytotoxic chemotherapies, hormone therapy, and radiotherapy in the cancers. These studies have highlighted the role of EGFR as an attractive therapeutic target in cisplatin-resistant EOC cells.

Methods

The human ovarian cell lines (SKOV3 and OVCAR3) were cultured according to ATCC recommendations. The MTT assay was used to determine the chemosensitivity of the cell lines in exposure to cisplatin and erlotin

SUBMITTER: Poursheikhani A 

PROVIDER: S-EPMC7601546 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature